Customer

April 15, 2026

How Omeicos Identified Biomarker Signals and Safety Trends with Rivia

Omeicos Therapeutics used Rivia's platform to manage their Phase 2a clinical trial for OMT-28, a drug for Primary Mitochondrial Disease. Their core challenge was fragmented data spread across multiple disconnected systems, which slowed safety monitoring and subgroup analysis. Rivia consolidated all trial data into one real-time environment, cutting reporting time from hours to minutes and enabling faster, more informed decisions throughout the entire trial lifecycle.

Stay Ahead with Rivia Insights

Join our newsletter for the latest industry trends, product updates, customer success stories, and partner highlights—delivered straight to your inbox.

Thank you, you are now subscribed!

Oops! Something went wrong while submitting the form.

Don't just manage your trials. Master them.

Unlock the power of seamless data integration for faster, smarter decisions.

Book a demo Contact us

Site by New Now

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Preferences

Our News

How Omeicos Identified Biomarker Signals and Safety Trends with Rivia